Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02747303 · ClinicalTrials.gov registry record · Phase 2
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
A Phase 2 study of Brain Metastases, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 166
- Enrollment target
- 1
- Study location
NCT02747303: Recruiting Phase 2 study of Brain Metastases, sponsored by University of Chicago.
NCT02747303 is a Phase 2 study of Brain Metastases that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 166 participants, below the 210-participant average among 67 other Brain Metastases trials with a reported enrollment target (21% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02747303, a Phase 2 study of Brain Metastases, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 166 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized study to determine if not treating planning target volume (PTV) margins during radiation therapy worsens progression free survival rates in patients with brain metastases.
Primary Outcome
Progression free survival (PFS) rates will be estimated by the Kaplan-Meier method and the 0-mm and 2-mm groups will be compared via the log-rank statistic with a one-sided test of significance, using follow-up data up to 6 months.
Conditions Studied
Interventions
- PROCEDURE Stereotactic Radiosurgery
Study Locations (1)
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2023-09-05 |
| Est. Completion | 2028-08-22 |
| Phase | Phase 2 |
What NCT02747303 shows while recruiting
NCT02747303 is an interventional study that assigns participants to a tested intervention. The registered 166 participants enrollment target is mid-sized for trials with a published cap, below the 210-participant average among 67 other Brain Metastases trials with a reported enrollment target (21% lower).
The record links to 1 condition, with Brain Metastases appearing as the primary indexed condition, and to 1 intervention - of which Stereotactic Radiosurgery is the first listed.
NCT02747303 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT02747303 about?
NCT02747303 is a clinical study titled "Frameless Stereotactic Radiosurgery for Intact Brain Metastases". This is a randomized study to determine if not treating planning target volume (PTV) margins during radiation therapy worsens progression free survival rates in patients with brain metastases.
What is the current status of trial NCT02747303?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 166 participants. The study started on 2023-09-05. Estimated completion is 2028-08-22.
What conditions does trial NCT02747303 study?
This clinical trial studies the following conditions: Brain Metastases.
What interventions are being tested in trial NCT02747303?
The interventions under investigation include: Stereotactic Radiosurgery (PROCEDURE).
Who is sponsoring clinical trial NCT02747303?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02747303 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02747303's enrollment target sits among peer trials
166 8th of 67 higher than 60 of 67 other Brain Metastases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Metastases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active
RECRUITING · Phase 2
-
Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis
RECRUITING · Phase 2
-
Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique
RECRUITING · Phase 2
-
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
RECRUITING · Phase 2
-
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
RECRUITING · Phase 2
-
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03806283 · 166 participants
Mechanisms of Pregnancy Vascular Adaptations
- NCT04040452 · 166 participants · Phase 4
Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery
- NCT04375813 · 166 participants · Phase 2
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
- NCT04501406 · 166 participants · Phase 2
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI